NeoGenomics raises 2026 guidance to $807M-$809M while planning CEO transition in January 2027 (NASDAQ:NEO)
seekingalpha.com · 2026-10-29
NeoGenomics Q3 2026: revenue rose 11%, NGS surged, and guidance increased.
Read the full story at seekingalpha.com →
Is NEO undervalued? See TickrTrends' fair value analysis →